We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Quanterix Completes Acquisition of Akoya Biosciences

By LabMedica International staff writers
Posted on 09 Jul 2025

Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. More...

The integration of Akoya’s spatial biology capabilities in tissue with Quanterix’s advanced tools for the ultra-sensitive detection of biomarkers in blood establishes the first fully integrated technology ecosystem to identify and measure biomarkers across tissue and blood. Quanterix is better positioned to serve research customers and ultimately clinicians with a broader set of technologies to improve diagnostic relevance and accuracy and enhance patient outcomes through biomarker-driven treatment decisions. With Quanterix’s industry-leading position in neurology and Akoya’s focus within oncology and immunology, Quanterix can expand its technology offerings across these high-growth markets.

The addition of Akoya’s cutting-edge spatial biology capabilities enables Quanterix to capitalize on growth opportunities in a USD5 billion serviceable addressable market. Leveraging Akoya’s established clinical partnerships and CLIA-certified lab services, Quanterix is now strategically positioned to drive significant value creation through an expanded portfolio of lab service offerings. This collaboration establishes a clear path for Quanterix to participate in the rapidly emerging spatial biology clinical market, particularly in oncology. Quanterix and Akoya have complementary offerings and deep customer relationships across discovery, translational, and clinical research.

“The acquisition of Akoya positions us to deliver comprehensive protein biomarker solutions that leverage signatures in blood and tissue, together providing a more holistic and predictive view of a patient’s disease,” said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. “This transaction extends our portfolio into new markets and is expected to expand our served addressable market from USD 1 billion to USD 5 billion. We believe the combined business will benefit from significant scale, a strong balance sheet and an accelerated path to profitability by 2026.”

Related Links:
Quanterix Corporation
Akoya Biosciences


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: USU chemists Kadin Crosby, Bamidele Filani, and Ryan Jackson have reported newly discovered functions of CRISPR-Cas12a3 (Photo courtesy of USU/M. Muffoletto)

CRISPR Discovery Paves Way for Single Diagnostic Test for COVID, Flu and RSV

Immune systems across all forms of life defend against viruses by blocking their ability to replicate. Many CRISPR-based defenses achieve this by cutting viral DNA, but these approaches can damage host... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.